胰高血糖素在危重症分解代谢与肌肉消耗中的作用及营养调控
该研究在人类和小鼠中通过输注宏量营养素及上调或下调胰高血糖素可用性,探讨胰高血糖素在危重症代谢紊乱和肌肉消耗中的作用。危重患者中,葡萄糖加胰岛素输注未降低胰高血糖素,而含氨基酸的肠外营养升高胰高血糖素。危重小鼠中,氨基酸输注升高胰高血糖素并上调肝脏氨基酸分解代谢标志物,但不影响肌肉消耗;免疫中和胰高血糖素仅短暂影响糖脂代谢,不影响肌肉消耗,但显著抑制肝脏氨基酸分解代谢标志物并逆转疾病诱导的低氨基酸血症。作者认为,危重症时胰高血糖素升高增加肝脏氨基酸分解代谢、解释低氨基酸血症,但不影响肌肉消耗且对血糖无持续影响;氨基酸输注可能通过升高胰高血糖素导致肝脏进一步分解氨基酸,而不预防肌肉消耗。
要点
- 危重患者中,葡萄糖加胰岛素输注未降低血浆胰高血糖素,而含氨基酸的肠外营养升高胰高血糖素。
- 危重小鼠中,氨基酸输注升高胰高血糖素并上调肝脏氨基酸分解代谢标志物,但未影响肌肉消耗。
- 危重小鼠中,免疫中和胰高血糖素仅短暂影响糖脂代谢,不影响肌肉消耗,但显著抑制肝脏氨基酸分解代谢标志物并逆转低氨基酸血症。
- 作者认为,危重症时胰高血糖素升高增加肝脏氨基酸分解代谢、解释低氨基酸血症,但不影响肌肉消耗且对血糖无持续影响。
- 作者认为,氨基酸输注可能通过升高胰高血糖素导致肝脏进一步分解氨基酸,而不预防肌肉消耗。
适用人群与场景
- 危重症患者(人类研究)及危重症小鼠(动物研究)
处置流程与药物剂量
- 危重患者中,输注葡萄糖加胰岛素未降低胰高血糖素;含氨基酸的肠外营养升高胰高血糖素。
- 危重小鼠中,输注氨基酸升高胰高血糖素并上调肝脏氨基酸分解代谢标志物,但不影响肌肉消耗。
- 危重小鼠中,免疫中和胰高血糖素仅短暂影响糖脂代谢,不影响肌肉消耗,但显著抑制肝脏氨基酸分解代谢标志物并逆转疾病诱导的低氨基酸血症。
研究设计与关键结果
- 研究在人类和小鼠中进行,通过输注宏量营养素及上调或下调胰高血糖素可用性,探讨其在危重症中的急性与慢性代谢作用。
- 危重患者中,葡萄糖加胰岛素输注未降低胰高血糖素,而含氨基酸的肠外营养升高胰高血糖素。
- 危重小鼠中,氨基酸输注升高胰高血糖素并上调肝脏氨基酸分解代谢标志物,但不影响肌肉消耗。
- 危重小鼠中,免疫中和胰高血糖素仅短暂影响糖脂代谢,不影响肌肉消耗,但显著抑制肝脏氨基酸分解代谢标志物并逆转疾病诱导的低氨基酸血症。
- 作者结论:危重症时胰高血糖素升高增加肝脏氨基酸分解代谢、解释低氨基酸血症,但不影响肌肉消耗且对血糖无持续影响;氨基酸输注可能通过升高胰高血糖素导致肝脏进一步分解氨基酸,而不预防肌肉消耗。
证据类型、等级与局限
- 临床试验注册号:NCT 00512122。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,危重症时升高的胰高血糖素增加肝脏氨基酸分解代谢、解释低氨基酸血症,但不影响肌肉消耗且对血糖无持续影响。
- 作者认为,氨基酸输注可能通过升高胰高血糖素导致肝脏进一步分解氨基酸,而不预防肌肉消耗。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
RATIONALE: Critical illness is hallmarked by muscle wasting and disturbances in glucose, lipid, and amino acid homeostasis. Circulating concentrations of glucagon, a catabolic hormone that affects these metabolic pathways, are elevated during critical illness. Insight in the nutritional regulation of glucagon and its metabolic role during critical illness is lacking.
OBJECTIVES: To evaluate whether macronutrient infusion can suppress plasma glucagon during critical illness and study the role of illness-induced glucagon abundance in the disturbed glucose, lipid, and amino acid homeostasis and in muscle wasting during critical illness.
METHODS: In human and mouse studies, we infused macronutrients and manipulated glucagon availability up and down to investigate its acute and chronic metabolic role during critical illness.
MEASUREMENTS AND MAIN RESULTS: In critically ill patients, infusing glucose with insulin did not lower glucagon, whereas parenteral nutrition containing amino acids increased glucagon. In critically ill mice, infusion of amino acids increased glucagon and up-regulated markers of hepatic amino acid catabolism without affecting muscle wasting. Immunoneutralizing glucagon in critically ill mice only transiently affected glucose and lipid metabolism, did not affect muscle wasting, but drastically suppressed markers of hepatic amino acid catabolism and reversed the illness-induced hypoaminoacidemia.
CONCLUSIONS: These data suggest that elevated glucagon availability during critical illness increases hepatic amino acid catabolism, explaining the illness-induced hypoaminoacidemia, without affecting muscle wasting and without a sustained impact on blood glucose. Furthermore, amino acid infusion likely results in a further breakdown of amino acids in the liver, mediated by increased glucagon, without preventing muscle wasting. Clinical trial registered with www.clinicaltrials.gov (NCT 00512122).
参考来源
- Thiessen SE, Derde S, Derese I, et al. Role of Glucagon in Catabolism and Muscle Wasting of Critical Illness and Modulation by Nutrition. Am J Respir Crit Care Med. 2017. PMID: 28475354. doi:10.1164/rccm.201702-0354OC
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。